Technology areas: Biotechnology & Pharmaceuticals • Communications • Semiconductors, Circuits & Optics • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Genemind Biosciences Co. Ltd. is currently navigating 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units and 5 distinct examiners. HERNANDEZ, JACKSON J is the busiest examiner, responsible for 1 pending office action. This data shows that each of the 5 pending actions is being handled independently by a different examiner in a unique art unit.
The involvement of 5 distinct examiners across 5 distinct art units indicates a highly decentralized prosecution environment. For practitioners, this means that the outcome of each of the 5 pending office actions will depend on the specific standards of the individual examiner, such as HERNANDEZ, JACKSON J. There is no concentration of cases that would allow for a unified negotiation strategy with a single department. Instead, the Biotechnology & Pharmaceuticals portfolio requires a multi-faceted approach that accounts for the diverse examination cultures present across all 5 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 50.7% | +39.2% |
| WHALEY, PABLO S | 1 | 25.0% | +21.3% |
| MILIA, MARK R | 1 | 59.0% | +22.2% |
| MERLIN, JESSICA M | 1 | 61.8% | +24.1% |
| CROW, ROBERT THOMAS | 1 | 41.6% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020915 | AMINO-MODIFIED CHIP, PREPARATION METHOD THEREFOR AND USE THEREOF | CROW, ROBERT THOMAS | 29d |
| 18999061 | METHOD AND APPARATUS FOR DETECTING CHROMOSOMAL ANEUPLOIDY, DEVICE AND STORAGE MEDIUM | WHALEY, PABLO S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18880793 | SURFACE TREATMENT METHOD, SEQUENCING METHOD, AND KIT | HERNANDEZ, JACKSON J | 30d overdue |
| 18020915 | AMINO-MODIFIED CHIP, PREPARATION METHOD THEREFOR AND USE THEREOF | CROW, ROBERT THOMAS | 29d |
| 18999061 | METHOD AND APPARATUS FOR DETECTING CHROMOSOMAL ANEUPLOIDY, DEVICE AND STORAGE MEDIUM | WHALEY, PABLO S | — |
| 18950631 | METHOD AND APPARATUS FOR DETERMINING INTER-CHANNEL CROSSTALK CORRECTION STRENGTH, AND MEDIUM | MILIA, MARK R | — |
| 18798368 | IMAGING SYSTEM AND SEQUENCING SYSTEM | MERLIN, JESSICA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 3619 | 1 |
| 2681 | 1 |
| 2871 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18880793 | SURFACE TREATMENT METHOD, SEQUENCING METHOD, AND KIT | HERNANDEZ, JACKSON J | 1627 | §112 | Final Rejection | 30d overdue | Pending | Jan 02, 2025 |
| 18999061 | METHOD AND APPARATUS FOR DETECTING CHROMOSOMAL ANEUPLOIDY, DEVICE AND STORAGE MEDIUM | WHALEY, PABLO S | 3619 | §101§102§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18950631 | METHOD AND APPARATUS FOR DETERMINING INTER-CHANNEL CROSSTALK CORRECTION STRENGTH, AND MEDIUM | MILIA, MARK R | 2681 | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18798368 | IMAGING SYSTEM AND SEQUENCING SYSTEM | MERLIN, JESSICA M | 2871 | §103 | Final Rejection | — | Pending | Aug 08, 2024 |
| 18020915 | AMINO-MODIFIED CHIP, PREPARATION METHOD THEREFOR AND USE THEREOF | CROW, ROBERT THOMAS | 1682 | §103§112 | Non-Final OA | 29d | Pending | Feb 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenemind Biosciences Co. Ltd. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Jackson J Hernandez has the most, with 1 of Genemind Biosciences Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
